BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy.

METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy.

RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001).

CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer. Copyright 2003 Massachusetts Medical Society

Written by:
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED.   Are you the author?
M.D. Anderson Cancer Center, Houston, USA.

Reference: N Engl J Med. 2003 Aug 28;349(9):859-66.

PubMed Abstract
PMID: 12944571




Upcoming Events
October 23-27, 2022
ASTRO is a professional association in radiation oncology that is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, the advancement of science and research, and advocacy.

Program and meeting information to be released soon!
October 27-29, 2022
2022 – 29th Annual Scientific Retreat

The Annual Prostate Cancer Foundation (PCF) Scientific Retreat is the foremost scientific conference in the world on the biology and treatment of prostate cancer. The diversity, novelty, and extremely high impact of the topics presented as well as the diversity and excellence of the invited attendees make this a unique conference. The PCF Scientific Retreat reflects the unyielding commitment of PCF to ending death and suffering from prostate cancer. This investment by PCF fosters a collaborative culture unparalleled in any other cancer research area and has accelerated the understanding of prostate cancer biology and the treatment landscape.

Omni La Costa, Carlsbad, CA

October 30-November 4, 2022
All Urology Professionals Welcome: The Western Section of the American Urological Association invites all AUA members and urology professionals around the world to join us for one of Urology’s top meetings. Experience UROLOGY UPGRADED - where we deliver the most cost-effective use of your time by combining superb value, top quality CME, world-class speakers, recreation and relaxation. Enjoy a wide variety of topics & content infused with comfort, hospitality and collegiality while immersing yourself in sessions that foster engagement, connections and learning. With over 450 urologists and 50 allied health attendees expected, the WSAUA Annual Meeting is the largest gathering of urology professionals in the Western U.S. Families are also welcome at the Western Section!

Who Should Attend?
Urologists • Urology Residents and Fellows • Doctors of Osteopathy • Advanced Practice Providers • Physician Assistants • Nurse Practitioners • Practice Managers • Industry Partners

Program Schedule 
November 4-5, 2022
The Kidney Cancer Association (KCA) presents the International Kidney Cancer Symposium, an opportunity for physicians, researchers, academics, and industry professionals from across the globe to join together and exchange ideas that will direct the future of kidney cancer research and treatment in the ultimate pursuit of a cure.

Location: Austin, Texas, USA
Hyatt Regency Austin
email news signup